Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

NCT00004635 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

159

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Thalidomide
DRUG: leuprolide acetate
DRUG: goserelin
OTHER: Placebo

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]